News

chronic lymphocytic leukemia/small lymphocytic leukemia, lymphoma

ASH 2021: Minimal Residual Disease Kinetics Identified as a Predictor of Zanubrutinib-Obinutuzumab-Venetoclax Treatment Response in CLL

Minimal residual disease (MRD) kinetics were found to be predictive of achievement and durability of undetectable MRD with zanubrutinib-obinutuzumab-venetoclax (BOVen) treatment in patients with chronic lymphocytic leukemia (CLL), according to trial results presented by LRF grantee Jacob D. Soumerai, MD of Massachusetts General Hospital Cancer Center.

lymphoma, Mantle Cell Lymphoma

ASH 2021: High MCL35 Score Is Predictive of Poor Survival in Older Patients with Mantle Cell Lymphoma Treated with Bendamustine-Rituximab

In a study funded in part by LRF and led by LRF Scientific Advisory Board (SAB) and Mantle Cell Lymphoma Consortium (MCLC) member Lisa M. Rimsza, MD, of Mayo Clinic, Phoenix, researchers examined the prognostic value of the MCL35 assay in older patients (aged 65-93) with MCL who were treated with frontline bendamustine (Treanda) plus rituximab (Rituxan).

cutaneous t-cell lymphoma, lymphoma

ASH 2021: No Difference in Survival Among Black Patients with Cutaneous T-Cell Lymphomas in Multicenter Analysis

Large registry studies in the United States have revealed lower rates of survival and a propensity for high-risk features in Black patients with mycosis fungoides and Sézary syndrome compared with other races and ethnicities.

Hodgkin Lymphoma, lymphoma

ASH 2021: Pembrolizumab Plus HDAC Inhibition Exhibits High Response Rates for Hodgkin Lymphoma in Early Study

Response rates to pembrolizumab (Keytruda) plus vorinostat (Zolinza), a histone deacetylase (HDAC) inhibitor, were high in anti-PD1 naïve/sensitivity relapsed/refractory Hodgkin lymphoma (HL), according to a study funded in part by LRF and presented by LRF grantee Alex F. Herrera, MD, of City of Hope.

follicular lymphoma, lymphoma

ASH 2021: Long-Term Follow-Up Reveals Superiority of Maintenance Rituximab Therapy Over Retreatment Strategy in Low Tumor Burden Follicular Lymphoma

In a long-term follow-up of the RESORT study, maintenance rituximab (Rituxan) delayed time to first cytotoxic therapy (a substance that kills cells, including cancer cells.

lymphoma

LRF Releases 2022 Public Policy Agenda Outlining Priorities for Year Ahead

The Public Policy Agenda outlines LRF's policy priorities for the year ahead and will direct the efforts of thousands of patient and caregiver advocates across the United States.

lymphoma

What Lymphoma Patients Need to Know About the Approved Preventative COVID-19 Antibody

On December 8, 2021, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld, a monoclonal antibody combination of tixagevimab and cilgavimab.

chronic lymphocytic leukemia/small lymphocytic leukemia, lymphoma

Ask the Doctor: What is the difference between a partial response to testing and having undetectable MRD?

Ask the Doctor: What is the difference between a partial response to testing and having undetectable minimal residual disease (MRD)? People with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) can have a range of responses after treatment. Testing is done…

lymphoma

LRF Scientific Leadership and Investment in Innovative Research Highlighted at 2021 American Society of Hematology Annual Meeting

LRF Scientific Advisory Board Members Joined by Current and Former Grantees at the 63rd ASH Annual Meeting & Exposition

burkitt lymphoma, diffuse large b-cell lymphoma, lymphoma

U.S. Food and Drug Administration Approves Rituximab (RITUXAN) Plus Chemotherapy for Pediatric B-cell Lymphomas

Rituximab (RITUXAN, Genentech, Inc.), a monoclonal antibody, has been approved in combination with chemotherapy for pediatric patients 6-18 months with previously untreated, advanced staged, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), and Burkitt-like lymphoma (BLL).

Subscribe to Our Emails. Get lymphoma and CLL resources and updates.